Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Debottlenecking R&D with Automated Powder Dispensing

The Enabling Technologies Consortium™ (ETC) - group of major pharmaceutical and biotechnology companies  - has published a new study on powder dispensing with the aim of easing R&D bottlenecks, particularly in high-throughput experimentation.

In an effort to understand the relative merits and disadvantages of existing automated powder dispensing technologies, an independent evaluation was carried out by the ETC's High Throughput Experimentation (HTE) working group. This working group comprised of AstraZeneca (AZ), Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Merck & Co., and Pfizer. The study evaluated four commercially available automated powder dispensing platforms, including Quantos from METTLER TOLEDO, to assess their abilities to accurately weigh a wide range of different powder types into vials.

The results of this benchmarking study, entitled "Collaborative Evaluation of Commercially Available Automated Powder Dispensing Platforms for High Throughput Experimentation in Pharmaceutical Applications", were presented at Pittcon 2018 [1] and will be published in OPRD [2].

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register